FDA Orange Book · active-ingredient family
Loxapine hydrochloride
Loxapine hydrochloride: 2 brands, 0 generics.
Brand onlyHas discontinued products
Generic status & protection
No listed patents or exclusivity — brand product(s) only.
Brands (NDA)
2
Generics (ANDA)
0
Listed patents
0
Presentations
2
Originator applications
Brand (NDA) products
TEVA BRANDED PHARMNDA 017658—
TEVA BRANDED PHARMNDA 017658—
| Strength | Dosage form | Route | Status | TE |
|---|---|---|---|---|
| EQ 25MG BASE/ML | CONCENTRATE | ORAL | Discontinued | — |
ACTAVIS LABS UT INCNDA 018039—
ACTAVIS LABS UT INCNDA 018039—
| Strength | Dosage form | Route | Status | TE |
|---|---|---|---|---|
| EQ 50MG BASE/ML | INJECTABLE | INJECTION | Discontinued | — |
Orange Book patent file
Listed patents
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Loxapine hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
